CCT 137690CAS号: 1095382-05-0分子式: C26H31BrN8O分子量: 551.48描述纯度储存/保存方法别名可溶性/溶解性靶点In vitro(体外研究)In vivo(体内研究)参考文献
产品描述 | |
描述 |
CCT137690是一种高选择性Aurora A, Aurora B和Aurora C抑制剂,IC50分别为15 nM, 25 nM和19 nM,对hERG离子通道几乎没有作用效果。CCT137690作用于多种人类肿瘤细胞系具有抗增殖活性,包括SW620结肠癌细胞和A2780卵巢癌细胞,GI50分别为0.3和0.14 μM。 此外 CCT137690也抑制组蛋白H3的磷酸化作用。CCT137690抑制主要的细胞色素P450亚型(CYP1A2,CYP2A6,CYP2C9,CYP2C19,CYP2D6, CYP3A4),IC50值大10 μM。 |
纯度 |
>98%
|
储存/保存方法 |
Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution.
|
基本信息 | |
别名 |
CCT137690
|
可溶性/溶解性 |
DMSO :55.2 mg/mL (100 mM)
|
生物活性 | |
靶点 |
Aurora A,Aurora C,Aurora B
|
In vitro(体外研究) |
CCT137690 displays antiproliferative activity in a range of human tumor cell lines, including SW620 colon carcinoma cell and A2780 ovarian cancer cell with GI50 of 0.3 and o.14 μM, respectively. In addition, CCT137690 also inhibit the phosphorylation of histone H3. CCT137690 inhibits the major cytochrome P450 isoforms (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP3A4) with IC50 greater than 10 μM. However, CCT137690 is a moderate inhibitor of the hERG ion-channel with IC50 of 3.0 μM. CCT137690 effectively inhibits the growth of human tumor cell lines of different origins with GI50 ranging from 0.005 to 0.47 μM. CCT137690 completely inhibits both Aurora A autophosphorylation at T288 and histone H3 phosphorylation at 0.5 μM. CCT137690 induces polyploidy, mitotic aberrations, and apoptosis in HCT116 cells. CCT137690 reduces MYCN levels and GSK3β phosphorylation in the KELLY neuroblastoma cell line. CCT137690 inhibits autophosphorylation of FLT3 and phosphorylation of its downstream targets STAT5 and p44/42 MAPK (Erk1/2).
|
In vivo(体内研究) |
CCT137690 is highly orally bioavailable and inhibits the growth of SW620 colon carcinoma xenografts with no observed toxicities as defined by body weight loss. CCT137690 inhibits growth of MYCN-induced neuroblastoma at a dose of 100 mg/kg. Additionally, CCT137690 achieves target modulation and potently inhibits the growth of subcutaneous MOLM-13 xenografts, with no obvious toxicity or loss of body weight.
|
参考文献 | |
参考文献 |
Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns.
Moore AS,et al. Leukemia. 2012 Jul;26(7):1462-70. PMID: 分子结构图
|